{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:06:59Z","timestamp":1791407219856,"version":"4.3.3"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004595","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) remains a leading cause of infectious disease death. New TB vaccines are currently in late-stage trials and may be available before the end of the decade. Modelling predicts new TB vaccines may reduce global burden but rely on assumptions about vaccine efficacy by TB disease stage and TB natural history, which may be incorrect. We explored the sensitivity of estimates of the impact of new TB vaccines to uncertainties in efficacy by disease stage and natural history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>We developed a dynamic compartmental TB model for India, including early TB disease stages (non-infectious disease, infectious asymptomatic disease, and infectious symptomatic disease). Scenarios assumed 50% vaccine efficacy for 10 years and prevented progression to (a) only infectious symptomatic disease, or (b) any infectious disease (infectious asymptomatic disease and infectious symptomatic disease), or (c) any disease (non-infectious disease, infectious asymptomatic disease, and infectious symptomatic disease). We estimated impact on averting disease episodes over 2030\u20132050, compared to no-new-vaccine introduction. Results suggest, over 3 years, there was little difference in the proportion of cumulative symptomatic disease episodes averted by vaccines preventing only infectious symptomatic disease, any infectious disease, or any disease (1.6%, 2.3%, and 2.3%, respectively). However, over 20 years, compared to vaccines preventing only infectious symptomatic disease, vaccines preventing any infectious disease, or any disease, averted a markedly higher proportion of symptomatic disease episodes (7.3%, 19.4%, and 23.3%, respectively), due to preventing continued transmission from infectious asymptomatic disease. A key limitation with any mathematical modelling study is the uncertainty associated with the inputs, and further data collection is required to better understand the transmissibility, morbidity, and dynamics of asymptomatic disease, to improve modelling estimates and inform wider policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our modelling estimates that the population impact of new TB vaccines may depend on efficacy against infectious asymptomatic disease. TB vaccine trials should include analyses of participant sputum samples (collected during or at the end of trials and analysed at the end of trials) to enable better estimates of the potential value of new TB vaccines against infectious asymptomatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004595","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:40:44Z","timestamp":1770921644000},"page":"e1004595","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5358-6932","authenticated-orcid":true,"given":"Hira","family":"Tanvir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-0301","authenticated-orcid":true,"given":"Rebecca A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-534X","authenticated-orcid":true,"given":"Tom","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-4065","authenticated-orcid":true,"given":"Katherine C.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-302X","authenticated-orcid":true,"given":"Tomos O.","family":"Pr\u0177s-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0944","authenticated-orcid":true,"given":"Roel","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-0780","authenticated-orcid":true,"given":"Kirankumar","family":"Rade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-4517","authenticated-orcid":true,"given":"Vidya","family":"Mave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-1809","authenticated-orcid":true,"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-3699","authenticated-orcid":true,"given":"Gavin J.","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4132-7467","authenticated-orcid":true,"given":"Rein M. G. J.","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-6635","authenticated-orcid":true,"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"pmed.1004595.ref001","unstructured":"Global Tuberculosis Report 2024 [Internet]. [cited 2025 Jan 15]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"pmed.1004595.ref002","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.82469","article-title":"Estimating the contribution of subclinical tuberculosis disease to transmission: an individual patient data analysis from prevalence surveys","volume":"12","author":"JC Emery","year":"2023","journal-title":"eLife"},{"issue":"4","key":"pmed.1004595.ref003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S2213-2600(18)30105-X","article-title":"Tuberculosis transmission during the subclinical period: could unrelated cough play a part?","volume":"6","author":"H Esmail","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"pmed.1004595.ref004","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1402","article-title":"Subclinical tuberculosis disease\u2014a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology","volume":"73","author":"B Frascella","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"pmed.1004595.ref005","doi-asserted-by":"crossref","first-page":"100895","DOI":"10.1016\/S2666-5247(24)00127-7","article-title":"Implications of subclinical tuberculosis for vaccine trial design and global effect","volume":"5","author":"GJ Churchyard","year":"2024","journal-title":"Lancet Microbe"},{"issue":"1","key":"pmed.1004595.ref006","first-page":"1","article-title":"Tuberculosis","volume":"2","author":"M Pai","year":"2016","journal-title":"Nat Rev Dis Primer"},{"issue":"2","key":"pmed.1004595.ref007","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.202006-2394PP","article-title":"The epidemiological importance of subclinical tuberculosis. A critical reappraisal","volume":"203","author":"EA Kendall","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"pmed.1004595.ref008","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5588\/ijtld.24.0081","article-title":"The International Consensus for Early TB Framework (ICE-TB): implications from a low-incidence setting","volume":"28","author":"JT Denholm","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"key":"pmed.1004595.ref009","unstructured":"Asymptomatic TB [Internet]. [cited 2025 Feb 12]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024\/featured-topics\/asymptomatic-tb"},{"issue":"5","key":"pmed.1004595.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00082-7","article-title":"Quantifying progression and regression across the spectrum of pulmonary tuberculosis: a data synthesis study","volume":"11","author":"AS Richards","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"25","key":"pmed.1004595.ref011","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"N Engl J Med"},{"key":"pmed.1004595.ref012","unstructured":"Bill & Melinda Gates Medical Research Institute. A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72\/AS01E-4 Mycobacterium Tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. 2025 Feb [cited 2025 Feb 12]. Report No.: NCT06062238. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06062238"},{"issue":"1","key":"pmed.1004595.ref013","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12916-023-02992-7","article-title":"New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent\/adult vaccination with M72\/AS01E and BCG-revaccination","volume":"21","author":"RA Clark","year":"2023","journal-title":"BMC Med"},{"issue":"4","key":"pmed.1004595.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00045-1","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study","volume":"11","author":"RA Clark","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"1","key":"pmed.1004595.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004155","article-title":"The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modeling study","volume":"20","author":"A Portnoy","year":"2023","journal-title":"PLoS Med"},{"issue":"7","key":"pmed.1004595.ref016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012466","article-title":"The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries","volume":"8","author":"A Portnoy","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"7","key":"pmed.1004595.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004252","article-title":"The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: a modeling study","volume":"20","author":"A Portnoy","year":"2023","journal-title":"PLoS Med"},{"key":"pmed.1004595.ref018","unstructured":"United Nations. Department of Economic and Social Affairs, Population Division. World Population Projections [2022 Revision] [Internet]. 2022 [cited 2025 Jan 23]. Available from: https:\/\/population.un.org\/wpp\/Download\/Standard\/Population\/"},{"key":"pmed.1004595.ref019","unstructured":"World Health Organization. Tuberculosis data [Internet]. [cited 2025 Jan 15]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data"},{"key":"pmed.1004595.ref020","unstructured":"Indian Council of Medical Research. Central TB Division, Ministry of Health and Family Welfare, Government of India. National TB prevalence survey in India. [Internet]. [cited 2025 Jan 15]. Available from: https:\/\/tbcindia.mohfw.gov.in\/wp-content\/uploads\/2023\/05\/25032022161020NATBPSReport.pdf"},{"issue":"4","key":"pmed.1004595.ref021","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5588\/ijtld.16.0182","article-title":"Estimating tuberculosis incidence from primary survey data: a mathematical modeling approach","volume":"21","author":"S Pandey","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"issue":"47","key":"pmed.1004595.ref022","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221186120","article-title":"Reevaluating progression and pathways following Mycobacterium tuberculosis infection within the spectrum of tuberculosis","volume":"120","author":"KC Horton","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pmed.1004595.ref023","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v109.i10","article-title":"Emulation and history matching using the hmer package","volume":"109","author":"A Iskauskas","year":"2024","journal-title":"J Stat Softw"},{"key":"pmed.1004595.ref024","unstructured":"Iskauskas A, McKinley TJ. hmer: History Matching and Emulation Package [Internet]. 2024 [cited 2025 Jan 15]. Available from: https:\/\/cran.r-project.org\/web\/packages\/hmer\/index.html"},{"key":"pmed.1004595.ref025","unstructured":"World Health Organization. WHO TB incidence estimates disaggregated by age group, sex and risk factor [Internet]. [cited 2025 Jan 23]. Available from: https:\/\/www.who.int\/tb\/country\/data\/download\/en\/"},{"key":"pmed.1004595.ref026","unstructured":"World Health Organization. WHO TB burden estimates [2022 revisions]. 2022. Available from: https:\/\/www.who.int\/tb\/country\/data\/download\/en\/"},{"key":"pmed.1004595.ref027","unstructured":"World Health Organization. Case Notifications [Internet]. [cited 2025 Jan 23]. Available from: https:\/\/www.who.int\/tb\/country\/data\/download\/en\/"},{"issue":"1","key":"pmed.1004595.ref028","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12916-017-0809-5","article-title":"Counting the lives saved by DOTS in India: a model-based approach","volume":"15","author":"S Mandal","year":"2017","journal-title":"BMC Med"},{"key":"pmed.1004595.ref029","article-title":"The potential impact, cost and cost-effectiveness of tuberculosis interventions\u2014a modelling exercise","author":"KC Horton","year":"2025","journal-title":"medRxiv"},{"issue":"564","key":"pmed.1004595.ref030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4607","article-title":"Potential impact of tuberculosis vaccines in China, South Africa, and India","volume":"12","author":"RC Harris","year":"2020","journal-title":"Sci Transl Med"},{"key":"pmed.1004595.ref031","unstructured":"WHO preferred product characteristics for new tuberculosis vaccines; 2018. Available from: https:\/\/www.who.int\/publications\/i\/item\/who-preferred-product-characteristics-for-new-tuberculosis-vaccines"},{"issue":"14","key":"pmed.1004595.ref032","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMoa1902129","article-title":"Community-wide screening for tuberculosis in a high-prevalence setting","volume":"381","author":"GB Marks","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"pmed.1004595.ref033","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5588\/ijtldopen.25.0177","article-title":"Willingness to accept new TB vaccines among adults, adolescents and their caregivers in a high TB burden setting","volume":"2","author":"KN Nelson","year":"2025","journal-title":"IJTLD Open"},{"key":"pmed.1004595.ref034","doi-asserted-by":"crossref","first-page":"101431","DOI":"10.1016\/j.smim.2020.101431","article-title":"Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis","volume":"50","year":"2020","journal-title":"Semin Immunol"},{"key":"pmed.1004595.ref035","unstructured":"The Stop TB Partnership Working Group on New TB Vaccines. Working group on new TB vaccines. 2022 [cited 2022 Dec 13]. TB Vaccine Pipeline. Available from: https:\/\/newtbvaccines.org\/tb-vaccine-pipeline\/"},{"issue":"10","key":"pmed.1004595.ref036","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(25)00164-X","article-title":"Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials","volume":"13","author":"RG White","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"8","key":"pmed.1004595.ref037","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00112-X","article-title":"Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?","volume":"4","author":"KN Nelson","year":"2023","journal-title":"Lancet Microbe"},{"issue":"1","key":"pmed.1004595.ref038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12916-023-02929-0","article-title":"The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making","volume":"21","author":"R Hutubessy","year":"2023","journal-title":"BMC Med"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004595","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:58:18Z","timestamp":1771873098000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004595"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004595","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}